Biotech major Biocon Thursday reported a rise of 78.22% in consolidated net profit at Rs 201.54 Cr for the Q4 ended March 31. This increase is supported by gains of Rs 105.06 Cr by the sale of shares of its research services subsidiary Syngene. The Q4 revenue rose 14.91% to Rs 830.38 Cr compared to same period a year ago.